Sandoz Group AG (OTCMKTS:SDZNY – Get Free Report) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $49.20 and last traded at $49.10, with a volume of 49059 shares changing hands. The stock had previously closed at $48.32.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the company. BNP Paribas lowered Sandoz Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 2nd. UBS Group cut Sandoz Group from a “strong-buy” rating to a “hold” rating in a report on Monday, February 3rd.
View Our Latest Report on Sandoz Group
Sandoz Group Price Performance
About Sandoz Group
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
Read More
- Five stocks we like better than Sandoz Group
- Most Volatile Stocks, What Investors Need to Know
- Digital Turbine Roars Back—What’s Driving the Ad Tech Surge?
- What Are the FAANG Stocks and Are They Good Investments?
- 6 Stocks Poised to Benefit From a Trade War in Unexpected Ways
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
